HALOPERIDOL tablet

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

HALOPERIDOL (UNII: J6292F8L3D) (HALOPERIDOL - UNII:J6292F8L3D)

Verfügbar ab:

REMEDYREPACK INC.

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

Haloperidol tablets are indicated for use in the management of manifestations of psychotic disorders. Haloperidol tablets are indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol tablets are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol tablets are also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol tablets should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. Haloperidol tablets are contraindicated in severe toxic central nervous system depression or comatose states from any caus

Produktbesonderheiten:

Haloperidol Tablets, USP are available containing 0.5 mg, 1 mg, 2 mg, 5 mg or 10 mg of haloperidol, USP. The 0.5 mg tablets are orange round tablets debossed with MYLAN over 351 on one side of the tablet and scored on the other side. They are available as follows: NDC 51079-733-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 1 mg tablets are orange round tablets debossed with MYLAN over 257 on one side of the tablet and scored on the other side. They are available as follows: NDC 51079-734-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 2 mg tablets are orange round tablets debossed with MYLAN over 214 on one side of the tablet and scored on the other side. They are available as follows: NDC 51079-735-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 5 mg tablets are orange round tablets debossed with MYLAN over 327 on one side of the tablet and scored on the other side. They are available as follows: NDC 51079-736-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 10 mg tablets are light green round tablets debossed with MYLAN over 334 on one side of the tablet and scored on the other side. They are available as follows: NDC 51079-431-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Distributed by: Mylan Institutional Inc. Rockford, IL 61103 U.S.A. S-12547 R1 6/19

Berechtigungsstatus:

Abbreviated New Drug Application

Fachinformation

HALOPERIDOL- HALOPERIDOL TABLET
REMEDYREPACK INC.
REFERENCE LABEL SET ID: 405EE4C4-394C-47DF-A6EC-9B4F4E7CA768
----------
WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED
PSYCHOSIS
ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH
ANTIPSYCHOTIC DRUGS ARE AT AN
INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED
TRIALS (MODAL DURATION OF
10 WEEKS), LARGELY IN PATIENTS TAKING ATYPICAL ANTIPSYCHOTIC DRUGS,
REVEALED A RISK OF DEATH IN
DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO 1.7 TIMES THE RISK OF DEATH IN
PLACEBO-TREATED
PATIENTS. OVER THE COURSE OF A TYPICAL 10-WEEK CONTROLLED TRIAL, THE
RATE OF DEATH IN DRUG-
TREATED PATIENTS WAS ABOUT 4.5%, COMPARED TO A RATE OF ABOUT 2.6% IN
THE PLACEBO GROUP.
ALTHOUGH THE CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED
TO BE EITHER
CARDIOVASCULAR (E.G., HEART FAILURE, SUDDEN DEATH) OR INFECTIOUS
(E.G., PNEUMONIA) IN NATURE.
OBSERVATIONAL STUDIES SUGGEST THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC
DRUGS, TREATMENT WITH
CONVENTIONAL ANTIPSYCHOTIC DRUGS MAY INCREASE MORTALITY. THE EXTENT TO
WHICH THE FINDINGS
OF INCREASED MORTALITY IN OBSERVATIONAL STUDIES MAY BE ATTRIBUTED TO
THE ANTIPSYCHOTIC DRUG
AS OPPOSED TO SOME CHARACTERISTIC(S) OF THE PATIENTS IS NOT CLEAR.
HALOPERIDOL IS NOT
APPROVED FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
(SEE WARNINGS).
DESCRIPTION
Haloperidol is the first of the butyrophenone series of major
tranquilizers. The chemical designation is
4-[4-(p-chloro-phenyl)-4-hydroxypiperidino]-4’—fluorobutyrophenone
and it has the following
structural formula:
Haloperidol is supplied as tablets for oral administration containing
0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg or
20 mg of haloperidol, USP and contains the following inactive
ingredients: colloidal silicon dioxide,
FD&C Yellow No. 6 Aluminum Lake, magnesium stearate, microcrystalline
cellulose, pregelatinized
starch and sodium lauryl sulfate. In addition, the 10 mg and 20 mg
tablets also contain FD&C Blue No. 1
Aluminum Lake.
CLINICAL PHARMACOLOG